Abstract
The recent success of the first FDA-approved small-molecule tyrosine kinase inhibitor Gleevec (STI-571, imatinib mesylate) in the treatment of chronic myelogenous leukemia (CML) has focused attention on the potential therapeutic usefulness of inhibitors of other kinase targets. This review shall highlight recent applications of computational chemistry methods, comprising both ligand-based and structure-based approaches, in the discovery and design of kinase inhibitors. In particular, we will focus on ATP-competitive inhibitors of selected kinase targets of therapeutic importance.
Keywords: kinase inhibitor, gleevec, imatinib mesylate, cml, chronic myelogenous leuremig, comfa, comsia
Current Pharmaceutical Design
Title: The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors
Volume: 8 Issue: 17
Author(s): John R. Woolfrey and G. Scott Weston
Affiliation:
Keywords: kinase inhibitor, gleevec, imatinib mesylate, cml, chronic myelogenous leuremig, comfa, comsia
Abstract: The recent success of the first FDA-approved small-molecule tyrosine kinase inhibitor Gleevec (STI-571, imatinib mesylate) in the treatment of chronic myelogenous leukemia (CML) has focused attention on the potential therapeutic usefulness of inhibitors of other kinase targets. This review shall highlight recent applications of computational chemistry methods, comprising both ligand-based and structure-based approaches, in the discovery and design of kinase inhibitors. In particular, we will focus on ATP-competitive inhibitors of selected kinase targets of therapeutic importance.
Export Options
About this article
Cite this article as:
Woolfrey R. John and Weston Scott G., The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors, Current Pharmaceutical Design 2002; 8 (17) . https://dx.doi.org/10.2174/1381612023394304
DOI https://dx.doi.org/10.2174/1381612023394304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MALT Lymphoma, Stress Ulcer and Cholinergic Nerves from the Viewpoint of Bilateral and Unilateral Truncal Vagotomy and Substance P
Current Pharmaceutical Design Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Prognosis, Significance and Positive Correlation of Rab1A and p-S6K/Gli1 Expression in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis
Current Medicinal Chemistry Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets 11 Years of Cyanopyrrolidines as DPP-IV Inhibitors
Current Topics in Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Multi-target Pharmacological Effects of Platycodin D
Mini-Reviews in Organic Chemistry Therapeutic Dilemma in Personalized Medicine
Current Reviews in Clinical and Experimental Pharmacology Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Tumor Necrosis Factor-α-Mediated Pulmonary Endothelial Barrier Dysfunction
Current Respiratory Medicine Reviews Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters